Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 6, 2008, Pages 529-538

  Resch, Bernhard ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bronchopulmonary dysplasia; Congenital heart disease; Cost effectiveness analysis; Incremental cost effectiveness ratios; Monoclonal antibody; Palivizumab; Preterm infant; Quality adjusted life years; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; PLACEBO;

ARTICLE; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; INFANT MORTALITY; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; PREMATURITY; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; VIRUS INFECTION;

EID: 68649092343     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.6.529     Document Type: Article

References (117)

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344, 1917-1928 (2001).
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282, 1440-1446 (1999).
3. Glezen WP, Taber LH, Frank AL, Kasel JH. Risk of primary infection and reinfection with respiratory-syncytial virus. AJDC 140, 543-546 (1986).
4. Simoes EAR Respiratory syncytial virus infection. Lancet 354, 847-852 (1999).
5. Arnold SR, Wang EE, Law Bj et al.; Pediatric Investigators Collaborative Network on Infections in Canada. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr. Infect. Dis. J. 18, 866-869 (1999).
6. Wilkesmann A, Ammarm RA, Schildgen O et al.; the DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course, Pediatr. Infect. Dis. J. 26, 485-491 (2007).
7. Meert K, Heidemann S, Abella B, Saeniak A. Does prematurity alter the course of respiratory syncytial virus infection? Crit. Care Med. 18, 1357-1359 (1990).
8. Kristensen K, Dahm T, Frederiksen PS et al. Epidemiology of respiratory syncytial virus infection requiring hospitalisation in East Denmark. Pediatr. Infect. Dis. J. 17, 996-1000 (1998).
9. Resch B, Gusenleitner W, Maller W. The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 30, 193-197 (2002).
10. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N. Engl. J. Med. 307, 397-400 (1982).
11. Navas L, Wang EEL, de Carvalho V, Robinson J; the PICNIC study group. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J. Pediatr. 121, 348-354 (1992).
12. Altman CA, Englund JA, Demmler G et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of pre-operative screening. Pediatr. Cardiol. 21, 433-438 (2000).
13. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J. Pediatr. 143, S150-S156 (2003).
14. Chevret L, Mbieleu B, Essouri S, Durand P, Chevret S, Devictor D. Bronchiolitis treated with mechanical ventilation: prognosis factor and outcome in a series of 135 children. Arch. Pediatr. 12, 385-390 (2005).
15. Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit, Care Med. 171, 137-141 (2005).
16. Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr. Pulmonol. 38, 155-160 (2004).
17. Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224 (1997).
18. DeVincenzo JP, Hall CB, Kimberlin DW et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizurnab (Synagis) -resistant mutants. J. Infect. Dis. 190(5), 975-978 (2004)
19. DeVincenzo JP, Aitken J, Harrison L. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J. Pediatr. 143, 123-126 (2003).
20. Malley R, DeVincenzo J, Ramilo 0 et a. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178, 1555-1561 (1998).
21. Subramanian KNS, Weisman LE, Rhodes T et al.; the MEDI-493 Study group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17, 110-115 (1998).
22. The IMpact-RSV Study Group. Palivizurnab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
23. American Academy of Paediatrics. Prevention of respiratory syncytial virus infections: indications for use of of palivizurnab and update on the use of RSV-IGIV. Paediatrics 102, 1211-1216 (1998).
24. Feltes TF, Cabalka AK, Meissner C et al. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143, 532-540 (2003).
25. American Academy of Paediatrics. Revised indications for the use of palivizumab and RSV-IGIV for the prevention of respiratory syncytial virus infection. Pediatrics 112, 1442-1452 (2003).
26. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 and 1999 respiratory syncytial virus season: the Palivizumab Outcomes Study Group. Pediatr. Infect. Dis. 119 (11), 1068-1071 (2000).
27. Parnes C, Guillermin J, Habersang R et al.; Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr. Pulmonol. 35(6), 484-489 (2003).
28. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr. Infect. Dis. J. 22(2 Suppl.), S46-S54 (2003).
29. Cohen SA, Zanni R, Cohen A, Harrington M, Van Veldhuisen P. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 palivizumab outcomes registry. Pediatr. Cardiol. 29(2), 382-387 (2008).
30. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr. Pulmonol. 41, 1167-1174 (2006).
31. Simoes EAP, Groothuis JR, Carbonell-Estrany X et al.; the Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151, 34-42 (2007).
32. Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health 7(l), 79-92 (2004).
33. Leader S, Jacobson P, Marcin J, Vardis R, Sorrentino M, Murray D. A method for identifying the financial burden of hospitalized infants on families. Value Health 5(1), 55-59 (2002).
34. Leader S, Yang H, DeVicenzo J, Jacobson P, Marcin J, Murray D. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health 6 (2), 100-106 (2003).
35. Greenough A, Cox S, Alexander J et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch. Dis. Child. 55, 463-468 (2001).
36. Greenough A, Alexander J, Burgess S et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch. Dis. Child. 89, 673-678 (2004).
37. Broughton S, Roberts A, Fox G et al. Prospective study ofhealthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax 60, 1039-1044 (2005).
38. Howard TS, Hoffman LH, Stang PE, Simoes EAR Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J. Pediatr. 137, 227-232 (2000).
39. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22(5), 275-284 (2004).
40. Langley JM, Wang EE, Law BJ et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J. Pediatr. 131 (1), 113-117 (1997).
41. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J. Pediatr. 143, S133-S141 (2003).
42. Chan PWK, Abdel-Latif MEA. Cost of hospitalisation for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr. 92, 481-485 (2003).
43. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 104 (3), 419-427 (1999).
44. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin. Ther. 21(4), 752-766 (1999).
45. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr. Adolesc. Med. 154(1), 55-61 (2000).
46. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr. Child Health 36 (5), 422-427 (2000).
47. Lofland JH, O'Connor JP, Chatterton ML et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin. Ther. 22(11), 1357-1369 (2060).
48. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation. for RSV infection in ex-peterm infants - implications for use of RSV immune globulin. Arch. Dis. Child. 83(2), 122-127 (2000).
49. Clark SJ, Beresford MW, Subhedat NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch. Dis. Child. 83 (4), 313-316 (2000).
50. Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impict of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med. Wkly 131, 146-151 (2001).
51. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann. Pharmacother. 35(10), 1186-1193 (2001).
52. Barton LL, Grant KL, Lemen R.J. Respiratory syncytial virus immune globulin: decisions and costs. Pediatr. Pulmonol. 32(1), 20-28 (2001).
53. Jacquemot L, Catelin C, Dobrzynski M, de Parscau L, Sizun J. Prevention of community-acquired respiratory syncytial virus infections in premature infants: cost-benefit evaluation in the Finistère Department. Arch. Pediatr. 9(2), 219-221 (2002).
54. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children. Arch. Pediatr. AdoLesc. Med. 156(12), 1251-1255 (2002).
55. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr. Pulmonol. 34, 262-266 (2002).
56. Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, Graham D, Grimwood K, Pattemore PK, Schousboe M. Cost-effectiveness of palivizumab in New Zealand. J. Paediatr. Child Health 38 (4), 352-357 (2002).
57. Fariña D, Rodríguez SP, Bauer G et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr. Infect. Dis. J. 21 (4), 287-291 (2002).
58. Vogel AM, Lennon DR, Broadbent R et al, Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J. Paediatr. Child Health 38 (6), 550-554 (2002).
59. Karnal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch. Pediatr. Adolesc. Med. 156(10), 1034-1041 (2002).
60. Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott. Med. J. 48 (4), 108-110 (2003).
61. Strutton DR, Stang PE. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making. J. Pediatr. 143 (5 Suppl.), S157-SI62 (2003)
62. Lapeña López de Armentia S, Robles García MB, Martínez Badás JP et al. Potential impact and cost-efficacy of bronchiolitis prophylaxis with palivizumab in preterin infants with a gestational age of less than 33 weeks. An. Pediatr. (Barc.) 59(4), 328-333 (2003).
63. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch. Dis. Child. 88 (12), 1065-1069 (2003).
64. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr. 162(4), 237-244 (2003).
65. Wegner S, Vann JJ, Liu G et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 114(6), 1612-1619 (2004).
66. Rietveld E, De Jonge HC, Polder JJ et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr. Infect. Dis. J. 23(6), 523-529 (2004).
67. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 114(6), 1606-1611 (2004).
68. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol. Young 15 (3), 251-255 (2005).
69. Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen 0. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch. Dis. Child. Fetal Neonatal Ed. 90(1), F64-F68 (2005).
70. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E et al. The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain. Ann. Pediatr. (Barc.) 65(4), 316-324 (2006).
71. Elhassan NO, Sorbero, ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch. Pediatr. Adolesc. Med. 160 (10), 1070-1076 (2006).
72. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects - hospitalizations and costs. Acta Paediatr. 95(4),404-406 (2006).
73. Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health 42(5), 253-258 (2006).
74. Nuijten MJ, Wittenberg W, Lebmeier M. Cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 25(1), 55-71 (2007).
75. Embleton ND, Dharmaraj ST, Deshpande S. Cost-effectiveness of palivizumab in infancy. Expert Rev. Pharmaeconomics Outcomes Res. 7(5), 445-458 (2007).
76. Resch B, Gusenleitner W, Nuijten MJC, Lebmeier M, Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin. Ther. 30(4), 749-760 (2008).
77. Rodriguez SP, Farina D, Bauer G. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis. Pediatr. Infect. Dis. J. 27(7), 660-661 (2008).
78. Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a powid of cure? Pediatrics 104, 559-560 (1999).
79. Groothuis JR. The pitfalls of using managed care databases in cost-effectiveness research. Pediatrics 104, 1124-1125 (1999).
80. Eppes SC. Questions about palivizumab (Synagis). Pediatrics 103 (2), 534-535; Author reply 535-536 (1999).
81. Moler FW, Brown RW, Faix RG, Gilsdorf JR. Comments on palivizumab (Synagis). Pediatrics 103, 495-497 (1999).
82. Seeler RA, Schatz B. Palivizumab (Synagis) - cohorting babies to reduce waste. Pediatrics 104, 1170-1171 (1999).
83. Carter BS. Palivizumab (synagis): counting "costs" and values. Pediatrics 106, 533-534 (2000).
84. Smith RA, Boon R. Economic disadvantages of palivizumab. Arch. Dis. Child. 82(4), 336 (2000).
85. Deshpande S. RSV prevention. Arch. Dis. Child. 82(1),88 (2000).
86. Moler F. Cost estimates of prophylaxis. Arch. Pediatr. Adolese. Med. 155 (2), 199-200 (2001).
87. Greisen G. Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection? Ugeskr. Laeger. 163 (47), 6607 (2001).
88. Robbins JM, Tilfford JM, Jacobs RJ, Wheeler JG, Gillaspy SR, Schutze GE. Costs and respiratory syncytial virus. Pediatrics 107(3), 608-609 (2001).
89. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther. Drug Monit. 24(3), 444-445 (2002).
90. Silverman W. A health care management company's experience with palivizumab. Manag. Care 11(1), 45-46. (2002).
91. Vergouwe Y, Steyerberg EW, Rietveld E, Moll HA. Comment: prophylaxis for RSV hospitalization may not be cost-saving. Ann. Pharmacother. 36(3), 534-535 (2002).
92. Klassen TB. Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion? Arch. Pediatr. Adolesc. Med. 156(12), 1180-1181 (2002).
93. Suresh S, Schilling S, Dakin C, Harris MA. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution. J. Paediatr. Child Health 39 (8), 637 (2003).
94. Heim EA, Cummings GE, Keane V, King JC Jr. Administration of palivizumab: a medical provider's perspective. Clin. Pediatr. (Phila.) 42(9), 821-826 (2003).
95. Marks AS. Indirect costs of respiratory syncytial virus hospitalizations: a commentary. Value Health 6(2), 98-99 (2003).
96. Stevens TP, Hall CB. Controversies in palivizumab use. Pediatr. Infect. Dis. J. 23 (11), 1051-1052 (2004).
97. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch. Dis. Child. Fetal Neonatal Ed. 90(4), F286-F289(2005).
98. Bala P, Ryan CA, Murphy BP. Hospital admissions for bronchiolitis in preterin infants in the absence of respiratory syncytial virus prophylaxis. Arch, Dis. Child. Fetal Neonatal Ed. 90(1), F92 (2005).
99. Van Rostenberghe HLA, Kew ST, Hanifah MJM. RSV and bronchiolitis. Arch. DIS. Child. Fetal Neonatal Ed. 91(2), F154 (2006).
100. Sunnegårdh J. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease - who should receive it? Acta Paediatr. 95(4), 388-390 (2006).
101. Mahadevia PJ, Malinoski FJ. Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab. Arch. Pediatr. Adolesc. Med. 161, 519-520 (2007).
102. Sorbero MES, ElHassan NO, Hall CB, Stevens TP, Dick AW. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab - reply. Arch. Pediatr. Adolesc. Med. 161, 520 (2007).
103. Grosse SD. Assessing cost-effectiveness in healthcare: history of the US$50,000 per. QALY threshold. Expert Rev. Pharmaeconomics Outcomes Res. 8(2), 165-178 (2008).
104. Mauskopf J, Rutten F, Schonfield W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 21(14), 991-1000 (2003).
105. Goldman L, Garber AM, Grover SA, Hlatky MA; Task force 6. Cost effectiveness of assessment and management of risk factors. JACC 27(5), 964-1030 (1996).
106. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr. 113, 826-830 (1988).
107. Garcia DF, Hiatt PW, Jewell A et al. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediarr. Pulmonol. 42, 66-74 (2007).
108. Madhi SA, Schoub B, Simmank K, Blackburn N, KJugmann KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J. Pediatr. 137, 78-84 (2000).
109. Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial virus infection in children with compromised immune function. N. Engl. J. Med. 315, 77-81 (1986).
110. Millner ME, de la Monte SM, Hutchins GM. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndromes. Am. J. Dis. Child. 139, 1111-1114 (1985).
111. Schneider S, Borzy MS. Fatal respiratory syncytial virus pneumonia as the presenting feature of severe combined immunodeficiency disease. Clin. Pediatr. (Phila.) 35, 147-149 (1996).
112. King JC Jr, Burke AR, Clemens JD et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr. Infect. Dis. J. 12, 733-739 (1993).
113. Resch B, Berger A, Bernert G et al. Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwe,gserkrankung. Monatsschr. Kinderheilkd 156, 381-383 (2008).
114. Mejias A, Chavez-Bueno S, Rios, AM et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV routine model: time versus potency. Antimicrob. Agents Chemother. 49, 4700-4707 (2005).
115. Wu H, Pfarr DS, Johnson S et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory sncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665 (2007).
116. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term β-adrenergic antagonists after acute myocardial infirction. N. Engl. J. Med. 319, 152-157 (1988).
117. Asensi F, De Jose M, Lorente M et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 7(1), 36-51 (2004).